News

ALS researchers worldwide continue to build upon existing work and make new discoveries in the hopes of realizing a world free of ALS. In the January 2025 Research Update, explore new insights into predicting disease onset, new potential therapies and…

Canada’s Drug Agency (CDA), formerly known as the Canadian Agency for Drugs and Technologies in Health (CADTH), has posted a call for patient input on tofersen, a therapy currently under review by Health Canada. This is an important opportunity for…

From December 2 to 8, 2024, the ALS Society of Canada (ALS Canada) and the ALS Society of Quebec (ALS Quebec) co-hosted a series of events that brought more than 1,500 delegates from around the world to Montreal to…

With support from Fondation Vincent Bourque, investments help seven early-career researchers and clinicians to improve ALS patient care and deepen our understanding of the disease TORONTO, December 18, 2024 – The ALS Society of Canada (ALS Canada) and Brain…

ALS Canada is proud to recognize and celebrate Dr. Richard Robitaille, a leader in ALS research and a professor at Université de Montréal, who has received the prestigious Drs. Ayeez and Shelena Lalji & Family ALS Endowed Award for Innovative…

ALS Canada Buck-A-Puck for ALS is back! This event unites young athletes and their passion for hockey with fundraising and awareness building for amyotrophic lateral sclerosis (ALS) – a disease that affects nearly 4,000 Canadians and their families. The concept…

Researchers, clinicians, allied health professionals, organizational leaders, industry, people living with ALS,and caregivers from around the world unite for a series of meetings focused on a shared goal of a world free of ALS TORONTO, November 28, 2024—This December,…

The ALS Society of Canada (ALS Canada) is committed to Canada’s contribution to global ALS research. We’re excited to share our involvement in the Accelerating Medicines Partnership® in Amyotrophic Lateral Sclerosis (AMP® ALS), led by the Foundation for the National…